Evaluation of nonischemic cardiomyopathies using cardiovascular magnetic resonance

Journal of Nuclear Cardiology

Volumn 15, Issue 3, 2008, Pages 400-416

  O'Hanlon, Rory ^a   Prasad, Sanjay K ^a   Pennell, Dudley J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; GADOLINIUM; IRON; IRON CHELATING AGENT;

AMYLOIDOSIS; CARDIOMYOPATHY; CHAGAS DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; FABRY DISEASE; HEART DISEASE; HEART LEFT VENTRICLE NONCOMPACTION; HEART RIGHT VENTRICLE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPEREOSINOPHILIA; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; IRON CHELATION; IRON OVERLOAD; MONOTHERAPY; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOMYOPATHIES; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MYOCARDIAL ISCHEMIA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 44249094215     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2008.03.006     Document Type: Review

References (103)

1. Maceira A.M., Prasad S.K., Khan M., and Pennell D.J. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 8 (2006) 417-426
2. Grothues F., Smith G.C., Moon J.C., Bellenger N.G., Collins P., Klein H.U., et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90 (2002) 29-34
3. Grothues F., Moon J.C., Bellenger N.G., Smith G.S., Klein H.U., and Pennell D.J. Interstudy reproducibility of right ventricular volumes, function and mass with cardiovascular magnetic resonance. Am Heart J 147 (2004) 218-223
4. Maceira A.M., Prasad S.K., Khan M., and Pennell D.J. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J 27 (2006) 2879-2888
5. Pan L., Stuber M., Kraitchman D.L., Fritzges D.L., Gilson W.D., and Osman N.F. Real-time imaging of regional myocardial function using fast-SENC. Magn Reson Med 55 (2006) 386-395
6. Keenan N.G., and Pennell D.J. CMR of ventricular function. Echocardiography 24 (2007) 185-193
7. Anand I., McMurray J., Cohn J.N., Konstam M.A., Notter T., Quitzau K., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 347-354
8. Prasad S.K., Dargie H.J., Smith G.C., Barlow M.M., Grothues F., Groenning B.A., et al. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: A cardiovascular magnetic resonance study. Heart 92 (2006) 798-803
9. Bellenger N.G., Davies L.C., Francis J.M., Coats A.J., and Pennell D.J. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2 (2000) 271-278
10. Bottini P.B., Carr A.A., Prisant L.M., Flickinger F.W., Allison J.D., Gottdiener J.S., et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 8 (1995) 221-228
11. Mohiaddin R.H., Gatehouse P.D., Henien M., and Firmin D.N. Cine MR Fourier velocimetry of blood flow through cardiac valves: Comparison with Doppler echocardiography. J Magn Reson Imaging 7 (1997) 657-663
12. Hartiala J.J., Mostbeck G.H., Foster E., Fujita N., Dulce M.C., Chazouilleres A.F., et al. Velocity-encoded cine MRI in the evaluation of left ventricular diastolic function. Measurement of mitral valve and pulmonary vein flow velocities and flow volume across the mitral valve. Am Heart J 125 (1993) 1054-1066
13. Fyrenius A., Wigström L., Bolger A.F., Ebbers T., Ohman K.P., Karlsson M., et al. Pitfalls in Doppler evaluation of diastolic function: Insights from 3-dimensional magnetic resonance imaging. J Am Soc Echocardiogr 12 (1999) 817-826
14. Rademakers F.E., Rogers W.J., Guier W.H., Hutchins G.M., Siu C.O., Weisfeldt M.L., et al. Relation of regional cross-fiber shortening to wall thickening in the intact heart. Three-dimensional strain analysis by NMR tagging. Circulation 89 (1994) 1174-1182
15. Paelinck B.P., Lamb H.J., Bax J.J., Van der Wall E.E., and de Roos A. Assessment of diastolic function by cardiovascular magnetic resonance. Am Heart J 144 (2002) 198-205
16. Likoff M.J., Chandler S.L., and Kay H.R. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 59 (1987) 634-638
17. Bart B.A., Shaw L.K., McCants Jr. C.B., Fortin D.F., Lee K.L., Califf R.M., et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 30 (1997) 1002-1008
18. Allman K.C., Shaw L.J., Hachamovitch R., and Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39 (2002) 1151-1158
19. Casolo G., Minneci S., Manta R., Sulla A., Del Meglio J., Rega L., et al. Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: Diagnostic accuracy of late gadolinium enhancement. Am Heart J 151 (2006) 101-108
20. McCrohon J.A., Moon J.C., Prasad S.K., McKenna W.J., Lorenz C.H., Coats A.J., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 (2003) 54-59
21. Bello D., Shah D.J., Farah G.M., Di Luzio S., Parker M., Johnson M.R., et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 108 (2003) 1945-1953
22. Soriano C.J., Ridocci F., Estornell J., Pérez-Boscá J.L., Pomar F., Trigo A., et al. Late gadolinium-enhanced cardiovascular magnetic resonance identifies patients with standardized definition of ischemic cardiomyopathy: A single centre experience. Int J Cardiol 116 (2007) 167-173
23. Bulkley B.H., Hutchins G.M., Bailey I., Strauss H.W., and Pitt B. Thallium 201 imaging and gated cardiac blood pool scans in patients with ischemic and idiopathic congestive cardiomyopathy: A clinical and pathological study. Circulation 55 (1977) 753-760
24. Wagner A., Mahrholdt H., Holly T.A., Elliott M.D., Regenfus M., Parker M., et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study. Lancet 361 (2003) 374-379
25. Barkhausen J., Hunold P., Jochims M., and Debatin J.F. Imaging of myocardial perfusion with magnetic resonance. J Magn Reson Imaging 19 (2004) 750-757
26. Assomull R.G., Prasad S.K., Lyne J., Smith G., Burman E.D., Khan M., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1977-1985
27. Nazarian S., Bluemke D.A., Lardo A.C., Zviman M.M., Watkins S.P., Dickfeld T.L., et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 112 (2005) 2821-2825
28. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331 (1994) 574-578
29. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89 (2004) 1187-1193
30. Modell B., Khan M., and Darlison M. Survival in beta thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 355 (2000) 2051-2052
31. Wacker P., Halperin D.S., Balmer-Ruedin D., Oberhansli I., and Wyss M. Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassaemia major. Chest 103 (1993) 1276-1278
32. Anderson L.J., Holden S., Davis B., Prescott E., Charrier C.C., Bunce N.H., et al. Cardiovascular T2-star (*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 21 (2001) 2171-2179
33. Tanner M.A., Galanello R., Dessi C., Westwood M.A., Smith G.C., Nair S.V., et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 8 (2006) 543-547
34. Anderson L.J., Westwood M.A., Holden S., Davis B., Prescott E., Wonke B., et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127 (2004) 348-355
35. Anderson L.J., Wonke B., Prescott E., Holden S., Walker J.M., and Pennell D.J. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 360 (2002) 516-520
36. Pennell D.J., Berdoukas V., Karagiorga M., Ladis V., Piga A., Aessopos A., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major in patients with asymptomatic myocardial siderosis. Blood 107 (2006) 3738-3744
37. Tanner M.A., Galanello R., Dessi C., Smith G.C., Westwood M.A., Agus A., et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115 (2007) 1876-1884
38. Tanner M.A., Galanello R., Dessi C., Smith G.C., Westwood M.A., Agus A., et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with severe left ventricular dysfunction. J Cardiovasc Magn Reson 10 (2008) 12
39. Modell B., Khan M., and Darlison M. Falling mortality and changing causes of death in thalassaemia major: Data from the UK thalassaemia register and possible contribution from T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2008) In press
40. Telfer P., Coen P.G., Christou S., Hadjigavriel M., Kolnakou A., Pangalou E., et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 91 (2006) 1187-1192
41. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., and Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in a CARDIA study. Circulation 92 (1995) 785-789
42. Maron B.J. Hypertrophic cardiomyopathy: A systematic review. JAMA 287 (2002) 1308-1320
43. Marian A.J., and Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 92 (1995) 1336-1347
44. Roberts R., and Sigwart U. New concepts in hypertrophic cardiomyopathy, part I. Circulation 104 (2001) 2113-2116
45. Maron B.J., McKenna W.J., Danielson G.K., Kappenberger L.J., Kuhn H.J., Seidman C.E., et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol 42 (2003) 1687-1713
46. Hughes S.E. The pathology of hypertrophic cardiomyopathy. Histopathology 44 (2004) 412-427
47. Klues H.G., Schiffers A., and Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 26 (1995) 1699-1708
48. Seidman J.G., and Seidman C.E. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 104 (2001) 557-567
49. Watkins H., McKenna W.J., Thierfelder L., Suk H.J., Anan R., O'Donoghue A., et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332 (1995) 1058-1064
50. Rickers C., Wilke N.M., Jerosch-Herold M., Casey S.A., Panse P., Panse N., et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 112 (2005) 855-861
51. Moon J.C., Fisher N.G., McKenna W.J., and Pennell D.J. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with nondiagnostic echocardiography. Heart 90 (2004) 645-649
52. Pennell D.J., Sechtem U.P., Higgins C.B., Manning W.J., Pohost G.M., Rademakers F.E., et al., Society for Cardiovascular Magnetic Resonance; Working Group on Cardiovascular Magnetic Resonance of the European Society of Cardiology. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 25 (2004) 1940-1965
53. Schulz-Menger J., Abdel-Aty H., Busjahn A., Wassmuth R., Pilz B., Dietz R., et al. Left ventricular outflow tract planimetry by cardiovascular magnetic resonance differentiates obstructive from non-obstructive hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 8 (2006) 741-746
54. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., and Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
55. Shirani J., Pick R., Roberts W.C., and Maron B.J. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 35 (2000) 36-44
56. Basso C., Thiene G., Corrado D., Buja G., Melacini P., and Nava A. Hypertrophic cardiomyopathy and sudden death in the young. Pathologic evidence of myocardial ischemia. Hum Pathol 31 (2000) 988-998
57. Varnava A.M., Elliott P.M., Sharma S., McKenna W.J., and Davies M.J. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84 (2000) 476-482
58. Choudhury L., Mahrholdt H., Wagner A., Choi K.M., Elliott M.D., Klocke F.J., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 2156-2164
59. Kuribayashi T., and Roberts W.C. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol 70 (1992) 1333-1340
60. Ursell P.C., Gardner P.I., Albala A., Fenoglio Jr. J.J., and Wit A.L. Structural and electrophysiological changes in the epicardial border zone of canine myocardial infarcts during infarct healing. Circ Res 56 (1985) 436-451
61. de Bakker J.M., van Capelle F.J., Janse M.J., Tasseron S., Vermeulen J.T., de Jonge N., et al. Slow conduction in the infarcted human heart: "Zigzag" course of activation. Circulation 88 (1993) 915-926
62. Kawara T., Derksen R., de Groot J.R., Coronel R., Tasseron S., Linnenbank A.C., et al. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 104 (2001) 3069-3075
63. Anyukhovsky E.P., Sosunov E.A., Plotnikov A., Gainullin R.Z., Jhang J.S., Marboe C.C., et al. Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res 54 (2002) 462-469
64. St John Sutton M.G., Lie J.T., Anderson K.R., O'Brien P.C., and Frye R.L. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J 44 (1980) 433-443
65. Harris K.M., Spirito P., Maron M.S., Zenovich A.G., Formisano F., Lesser J.R., et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114 (2006) 216-225
66. Cecchi F., Olivotto I., Gistri R., Lorenzoni R., Chiriatti G., and Camici P.G. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349 (2003) 1027-1035
67. Olivotto I., Cecchi F., Gistri R., Lorenzoni R., Chiriatti G., Girolami F., et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 47 (2006) 1043-1048
68. Maron B.J., Wolfson J.K., Epstein S.E., and Roberts W.C. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8 (1986) 545-557
69. Sipola P., Lauerma K., Husso-Saastamoinen M., Kuikka J.T., Vanninen E., Laitinen T., et al. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. Radiology 226 (2003) 129-137
70. Matsunaka T., Hamada M., Matsumoto Y., and Higaki J. First-pass myocardial perfusion and delayed contrast enhancement in hypertrophic cardiomyopathy assessed with MRI. Magn Reson Med Sci 2 (2003) 61-69
71. Knaapen P., van Dockum W.G., Götte M.J., Broeze K.A., Kuijer J.P., Zwanenburg J.J., et al. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: A PET and MRI study. J Nucl Cardiol 13 (2006) 660-667
72. Petersen S.E., Jerosch-Herold M., Hudsmith L., Robson M.D., Francis J.M., Doll H.A., et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: New insights from multiparametric magnetic resonance imaging. Circulation 115 (2007) 2418-2425
73. Casolo G., Di Cesare E., Molinari G., Knoll P., Midiri M., Fedele F., et al., Commissione di Studio di Risonanza Magnetica ed Imaging Integrato Cardiovascolare dell'ANMCO; Sezione di Studio de Cardioradiologia della Societa Italiana di Radiologia Medica; Gruppo di STudio Risonanza Magnetica della Societa Italiana di Cardiologia. Diagnostic work up of arrhythmogenic right ventricular cardiomyopathy by cardiovascular magnetic resonance (CMR). Consensus statement. Radiol Med (Torino) 108 (2004) 39-55
74. McKenna W.J., Thiene G., Nava A., Fontaliran F., Blomstrom-Lundqvist C., Fontaine G., et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy: Task force of the working group myocardial and pericardial disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 71 (1994) 215-218
75. Hamid M.S., Norman M., Quraishi A., Firoozi S., Thaman R., Gimeno J.R., et al. Prospective evaluation of relatives for arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol 40 (2002) 1445-1450
76. Burke A., Farb A., Tashko G., and Virmani R. Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: Are they different diseases?. Circulation 97 (1998) 1571-1580
77. Sen-Chowdhry S., Prasad S.K., Syrris P., Wage R., Ward D., Merrifield R., et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: Comparison with Task Force Criteria and genotype. J Am Coll Cardiol 48 (2006) 2132-2140
78. Sen-Chowdhry S., Syrris P., Ward D., Asimaki A., Sevdalis E., and McKenna W.J. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 115 (2007) 1710-1720
79. Feldman A.M., and McNamara D. Myocarditis. N Engl J Med 343 (2000) 1388-1398
80. Assomull R.G., Lyne J.C., Keenan N., Gulati A., Bunce N.H., Davies S.W., et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J 28 (2007) 1242-1249
81. Fabre A., and Sheppard M.N. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 92 (2006) 316-320
82. Puranik R., Chow C.K., Duflou J.A., Kilborn M.J., and McGuire M.A. Sudden death in the young. Heart Rhythm 2 (2005) 1277-1282
83. Simonetti O.P., Finn J.P., White R.D., Laub G., and Henry D.A. "black blood" T2-weighted inversion-recovery MR imaging of the heart. Radiology 199 (1996) 49-57
84. Friedrich M.G., Strohm O., Schulz-Menger J., Marciniak H., Luft F.C., and Dietz R. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 97 (1998) 1802-1809
85. Mahrholdt H., Goedecke C., Wagner A., Meinhardt G., Athanasiadis A., Vogelsberg H., et al. Cardiovascular magnetic resonance assessment of human myocarditis: A comparison to histology and molecular pathology. Circulation 109 (2004) 1250-1258
86. Mahrholdt H., Wagner A., Deluigi C.C., Kispert E., Hager S., Meinhardt G., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114 (2006) 1581-1590
87. Falk R.H., and Skinner M. The systemic amyloidoses: An overview. Adv Intern Med 45 (2000) 107-137
88. Maceira A.M., Joshi J., Prasad S.K., Moon J.C., Perugini E., Harding I., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 (2005) 186-193
89. Morgan J.M., Raposo L., and Gibson D.G. Cardiac involvement in Churg-Strauss syndrome shown by echocardiography. Br Heart J 62 (1989) 462-466
90. Rochitte C.E., Oliviera P.F., and Andrade J.M. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: A marker of disease severity. J Am Coll Cardiol 46 (2005) 1553-1558
91. Silverman K.J., Hutchins G.M., and Bulkley B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58 (1979) 1204-1211
92. Iwai K., Tachibana T., Hosoda Y., and Matsui Y. Sarcoidosis autopsies in Japan. Frequency and trend in the last 28 years. Sarcoidosis 5 (1988) 60-65
93. Bulkley B.H., Rouleau J.R., Whitaker J.Q., Strauss H.W., and Pitt B. The use of 201thallium for myocardial perfusion imaging in sarcoid heart disease. Chest 72 (1977) 27-32
94. Tadamura E., Yamamuro M., Kubo S., Kanao S., Saga T., Harada M., et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: Comparison with radionuclide imaging. AJR Am J Roentgenol 185 (2005) 110-115
95. Smedema J.P., Snoep G., van Kroonenburgh M.P., van Geuns R.J., Dassen W.R., Gorgels A.P., et al. Evaluation of the accuracy of gadolinium-enhanced CMR in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 (2005) 1683-1690
96. Jenni R., Wyss C.A., Oechslin E.N., and Kaufmann P.A. Isolated ventricular noncompaction is associated with coronary microcirculatory dysfunction. J Am Coll Cardiol 39 (2002) 450-454
97. Burke A., Mont E., Kutys R., and Virmani R. Left ventricular noncompaction: a pathological study of 14 cases. Hum Pathol 36 (2005) 403-411
98. Jenni R., Rojas J., and Oechslin E. Isolated noncompaction of the myocardium. N Engl J Med 340 (1999) 966-967
99. Oechslin E.N., Attenhofer Jost C.H., Rojas J.R., Kaufmann P.A., and Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: A distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol 36 (2000) 493-500
100. Kohli S.K., Pantazis A.A., Shah J.S., Adeyemi B., Jackson G., McKenna W.J., et al. Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: Time for a reappraisal of diagnostic criteria?. Eur Heart J 29 (2008) 89-95
101. Thomas L., and Sadick N. A case of Fabry disease mimicking hypertrophic cardiomyopathy. Heart Lung Circ 13 (2004) 188-190
102. Sachdev B., Takenaka T., Teraguchi H., Tei C., Lee P., McKenna W.J., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 (2002) 1407-1411
103. Moon J.C., Sachdev B., Elkington A.G., McKenna W.J., Mehta A., Pennell D.J., et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 (2003) 2151-2155